Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on United Therapeutics. The associated price target was lowered to $400.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors related to United Therapeutics’ ongoing clinical trials and potential market opportunities. The TETON trials, which are evaluating the use of nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF), are anticipated to provide significant data that could lead to regulatory approval and subsequent market launch by 2027. The trials are built on promising findings from the INCREASE trial, which showed notable improvements in lung function among IPF patients.
Despite some concerns from Key Opinion Leaders (KOLs) regarding the variability of lung function measurements and the absence of pulmonary hypertension testing in the TETON trials, there is optimism that positive results could secure approval for Tyvaso in treating IPF. The potential for Tyvaso to address a significant unmet need in the IPF market, coupled with the strategic trial design to mitigate confounding factors, supports Fein’s optimistic outlook and Buy rating for United Therapeutics.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $400.00 price target.